|The full article is available to subscribers||Subscriber Login|
The FDA has approved Duexis (Horizon), a fixed-dose combination of the nonsteroidal anti-inflammatory drug (NSAID) ibuprofen and the H2-receptor antagonist (H2RA) famotidine, for symptomatic relief of osteoarthritis and rheumatoid arthritis and to decrease the risk of developing gastric and duodenal ulcers in patients at risk for NSAID-associated ulcers. Vimovo, a combination of the NSAID naproxen and the proton pump inhibitor (PPI) esomeprazole, is also approved by the FDA for prevention of NSAID-associated gastric ulcers.1
NSAIDs AND GI TOXICITY — NSAIDs inhibit synthesis of prostaglandins, which have a protective effect on the gastric mucosa. They are more likely to cause gastric than duodenal ulcers.2 Up to 40% of chronic NSAID users report having dyspepsia, and 1-2% develop life-threatening consequences of peptic ulcer... more
5. ND Yeomans et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med 1998; 338:719.
7. ME Weinblatt et al. Efficacy, safety, and tolerability of HZT-501, including users of low-dose aspirin, a single-tablet combination of ibuprofen-famotidine: results of two phase 3 trials (abstract). Arthritis Rheum 2010; 62 suppl 10: 945.